Logo image of ICCC

IMMUCELL CORP (ICCC) Stock Fundamental Analysis

NASDAQ:ICCC - Nasdaq - US4525253062 - Common Stock - Currency: USD

5.02  +0.01 (+0.2%)

Fundamental Rating

2

ICCC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. ICCC may be in some trouble as it scores bad on both profitability and health. ICCC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ICCC has reported negative net income.
ICCC had a negative operating cash flow in the past year.
In the past 5 years ICCC always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: ICCC reported negative operating cash flow in multiple years.
ICCC Yearly Net Income VS EBIT VS OCF VS FCFICCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

With an excellent Return On Assets value of -8.57%, ICCC belongs to the best of the industry, outperforming 88.10% of the companies in the same industry.
ICCC has a Return On Equity of -14.43%. This is amongst the best in the industry. ICCC outperforms 89.88% of its industry peers.
Industry RankSector Rank
ROA -8.57%
ROE -14.43%
ROIC N/A
ROA(3y)-6.3%
ROA(5y)-4.96%
ROE(3y)-10.52%
ROE(5y)-7.93%
ROIC(3y)N/A
ROIC(5y)N/A
ICCC Yearly ROA, ROE, ROICICCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 -20

1.3 Margins

ICCC has a Gross Margin of 26.71%. This is in the better half of the industry: ICCC outperforms 74.78% of its industry peers.
ICCC's Gross Margin has declined in the last couple of years.
ICCC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.88%
GM growth 5Y-14.05%
ICCC Yearly Profit, Operating, Gross MarginsICCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

3

2. Health

2.1 Basic Checks

ICCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ICCC remains at a similar level compared to 1 year ago.
Compared to 5 years ago, ICCC has more shares outstanding
The debt/assets ratio for ICCC is higher compared to a year ago.
ICCC Yearly Shares OutstandingICCC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
ICCC Yearly Total Debt VS Total AssetsICCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of 1.57, we must say that ICCC is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.57, ICCC is doing good in the industry, outperforming 68.92% of the companies in the same industry.
ICCC has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.36, ICCC is doing worse than 73.36% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z 1.57
ROIC/WACCN/A
WACC8.98%
ICCC Yearly LT Debt VS Equity VS FCFICCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 3.11 indicates that ICCC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.11, ICCC is doing worse than 63.59% of the companies in the same industry.
ICCC has a Quick Ratio of 1.44. This is a normal value and indicates that ICCC is financially healthy and should not expect problems in meeting its short term obligations.
ICCC has a Quick ratio of 1.44. This is amonst the worse of the industry: ICCC underperforms 81.88% of its industry peers.
Industry RankSector Rank
Current Ratio 3.11
Quick Ratio 1.44
ICCC Yearly Current Assets VS Current LiabilitesICCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

ICCC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.02%, which is quite impressive.
ICCC shows a strong growth in Revenue. In the last year, the Revenue has grown by 46.34%.
ICCC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.72% yearly.
EPS 1Y (TTM)39.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)46.34%
Revenue growth 3Y4.43%
Revenue growth 5Y9.72%
Sales Q2Q%11.3%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ICCC Yearly Revenue VS EstimatesICCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
ICCC Yearly EPS VS EstimatesICCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ICCC. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICCC Price Earnings VS Forward Price EarningsICCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICCC Per share dataICCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ICCC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUCELL CORP

NASDAQ:ICCC (2/21/2025, 8:27:27 PM)

5.02

+0.01 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)02-25 2025-02-25/amc
Inst Owners13.58%
Inst Owner Change-92.25%
Ins Owners22.27%
Ins Owner Change0.14%
Market Cap44.73M
Analysts82.86
Price TargetN/A
Short Float %0.27%
Short Ratio1.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.88
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 1.7
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS2.68
BVpS2.96
TBVpS2.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.57%
ROE -14.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.71%
FCFM N/A
ROA(3y)-6.3%
ROA(5y)-4.96%
ROE(3y)-10.52%
ROE(5y)-7.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.88%
GM growth 5Y-14.05%
F-Score5
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.08%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.11
Quick Ratio 1.44
Altman-Z 1.57
F-Score5
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)111.86%
Cap/Depr(5y)114%
Cap/Sales(3y)15.28%
Cap/Sales(5y)16.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)46.34%
Revenue growth 3Y4.43%
Revenue growth 5Y9.72%
Sales Q2Q%11.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y48.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-210.09%
OCF growth 3YN/A
OCF growth 5YN/A